| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6117e0473538976d2f3232984ac3871e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ce4a80bf68d2d25f4505e03e9dfd1ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53af39112a7dc47e88c454ab5dcddf24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b5249eb0af2dd6f188a3056fda84955 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-90 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
2004-10-28^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-06-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1d73a2ff54fe6545fe526cea0f33d53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9047306b886714d68034fa2f628eff2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_631ecb2b24a5da87a12330e40363cc11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f21b7834a3909509298800bda7645e4 |
| publicationDate |
2009-06-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7541447-B2 |
| titleOfInvention |
Process for the preparation of an improved Brucella strain plasmid to develop the strain and the vaccine comprising the said strain |
| abstract |
A Brucella bacterium is modified by partial or complete deletion of the pgm gene, rendering the bacterium incapable of synthesizing a key enzyme in the metabolism of bacterial sugars. A live vaccine for immunization, prophylaxis or treatment of brucellosis comprises such a bacterium, either lyophilized or in a pharmaceutical vehicle. Nucleotide sequence fragments having the aforementioned deletion are disclosed, with methods for making them. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11717566-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248176-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10940193-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10220084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012016315-A1 |
| priorityDate |
2004-09-28^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |